Immutep Completes A$80 Million Capital Raise

Immutep (Formerly known as Prima Biomed) Limited has successfully completed an A$80 million capital raise to support its clinical development pipeline. The company, a clinical-stage biotechnology firm specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, believes that the new funding will fully support its current and expanded clinical program until Q1 CY2026. With a pro-form..